retatrutide ada 2025 results just delivered the first top-line Phase 3 for a triple agonist in obesity — and the findings from TRIUMPH-4 are striking👇 2025 ADA Highlights: A New

While a single instance isnt harmful, consistently doing so will compromise your results

Activity assays

This and other trials have shown improvements in patients lipid profiles with the most pronounced impact on reduction of triglycerides

These benchmarks are derived from the STEP clinical trial data and adjusted for real-world conditions where adherence and lifestyle factors vary more than in controlled studies

As new therapies emerge, clinicians face a critical question: which modern therapy offers the best outcomesGLP-1 agonists or SGLT2 inhibitors

One of the most common questions people ask before starting a GLP-1 medication is also one of the most hones